Provided by Tiger Trade Technology Pte. Ltd.

Novavax

9.36
-0.0625-0.66%
Volume:162.22K
Turnover:1.53M
Market Cap:1.54B
PE:-6.16
High:9.52
Open:9.42
Low:9.32
Close:9.42
52wk High:11.97
52wk Low:6.20
Shares:164.43M
Float Shares:143.00M
Volume Ratio:1.23
T/O Rate:0.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5181
EPS(LYR):2.58
ROE:-898.20%
ROA:-6.51%
PB:-8.07
PE(LYR):3.63

Loading ...

Novavax Inc. Stock Climbs 15.6%, Outperforms Peers

Dow Jones
·
May 07

Novavax Is Maintained at Hold by TD Cowen

Dow Jones
·
May 07

Why Novavax Stock Is Trading Higher On Wednesday?

Benzinga Earnings
·
May 07

Stock Track | Novavax Soars 17.35% Intraday After Beating Q1 Revenue Estimates on Vaccine Deals Strength

Stock Track
·
May 07

Novavax Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 06

Novavax Shares up 9% After Q1 Revenue Above Expectations

THOMSON REUTERS
·
May 06

BUZZ-U.S. STOCKS ON THE MOVE-Walt Disney, CVS, Uber

Reuters
·
May 06

Earnings Flash (NVAX) Novavax Posts Q1 Net Loss $0.06 a Share, vs. FactSet Est of $0.24 Loss

MT Newswires Live
·
May 06

Novavax Reports First Quarter 2026 Financial Results and Operational Highlights

THOMSON REUTERS
·
May 06

Novavax Outlook FY Adjusted Total Revenue USD 230-270 Million

THOMSON REUTERS
·
May 06

Novavax Inc FY2026 REV View $400.3 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
May 06

Novavax: Reiterates 2026 Revenue Framework, Combined R&D & SG&a Expense Guidance

THOMSON REUTERS
·
May 06

Novavax Shares Gain 6.2% Premarket After Q1 Revenue Above Expectations

THOMSON REUTERS
·
May 06

Novavax beats first-quarter revenue estimates on vaccine deals strength

Reuters
·
May 06

Novavax Inc - Q1 2026 Total Revenue $139.5 Mln - SEC Filing

THOMSON REUTERS
·
May 06

Novavax Inc - Q1 2026 Basic EPS $-0.06 VS $3.22; Diluted EPS $-0.06 VS $2.93 in Q1 2025 - SEC Filing

THOMSON REUTERS
·
May 06

Novavax Inc Q1 Shr View $-0.23, REV View $78.3 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
May 06

Novavax Q1 FY26 net loss widens to $9.5 million; revenue drops to $139.5 million

Reuters
·
May 06

TD Cowen’s Steve Scala Maintains Hold on NVAX, Nudges Price Target Up Amid Improved Tolerability Data but Limited Real‑World Effectiveness Evidence

TIPRANKS
·
May 06

Assessing Novavax (NVAX) Valuation As Licensing Pivot And Key Vaccine Readout Approach

Simply Wall St.
·
May 04